Xyrem (Sodium Oxybate)
|
|
- Brenda Horn
- 5 years ago
- Views:
Transcription
1 Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules Logic diagram: a visual depiction of the clinical criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable Note: Click the hyperlink to navigate directly to that section. Revision Notes Updated step 1 of logic diagram, page 4. Yes = deny; No = go to #2 December 27, 2018 Copyright 2018 Health Information Designs, LLC 1
2 Drugs Requiring Prior Authorization Drugs Requiring Prior Authorization XYREM 500 MG/ML ORAL SOLUTION December 27, 2018 Copyright 2018 Health Information Designs, LLC 2
3 Clinical Criteria Logic 1. Is the client less than (<) 16 years of age? [ ] Yes (Deny) [ ] No (Go to #2) 2. Does the client have a diagnosis of alcohol or substance abuse in the last 730 days? [ ] Yes (Deny) [ ] No (Go to #3) 3. Does the client have an active claim for a CNS depressant agent? [ ] Yes (Deny) [ ] No (Go to #4) 4. Is the requested dose per day less than or equal to ( ) 9 grams? [ ] Yes (Go to #5) [ ] No (Deny) 5. Does the client have a diagnosis of narcolepsy or cataplexy in the last 730 days? [ ] Yes (Approve 365 days) [ ] No (Deny) December 27, 2018 Copyright 2018 Health Information Designs, LLC 3
4 Clinical Criteria Logic Diagram Step 1 Step 2 Step 3 Is the client < 16 years of age? No Does the client have a diagnosis of alcohol or substance abuse in the last 730 days? No Does the client have an active claim for a CNS depressant agent? Yes Deny Request Yes Yes No Step 4 Deny Request Deny Request Is the requested dose per day 9 grams for the client? No Deny Request Yes Step 5 Approve Request (365 days) Yes Does the client have a diagnosis of narcolepsy or cataplexy in the last 730 days? No Deny Request December 27, 2018 Copyright 2018 Health Information Designs, LLC 4
5 Clinical Criteria Supporting Tables ICD-10 Code F1010 F10120 F10129 F1020 F1021 F10220 F10229 F1110 F11120 F11129 F1120 F1121 F11220 F11221 F11222 F11229 F1123 F1124 F11250 F11251 F11259 F11281 F11282 F11288 F1129 F1190 F1210 Step 2 (diagnosis of alcohol or substance abuse) Description Required diagnosis: 1 Look back timeframe: 730 days ALCOHOL ABUSE, UNCOMPLICATED ALCOHOL ABUSE WITH INTOXICATION, UNCOMPLICATED ALCOHOL ABUSE WITH INTOXICATION, UNSPECIFIED ALCOHOL DEPENDENCE, UNCOMPLICATED ALCOHOL DEPENDENCE, IN REMISSION ALCOHOL DEPENDENCE WITH INTOXICATION, UNCOMPLICATED ALCOHOL DEPENDENCE WITH INTOXICATION, UNSPECIFIED OPIOID ABUSE, UNCOMPLICATED OPIOID ABUSE WITH INTOXICATION, UNCOMPLICATED OPIOID ABUSE WITH INTOXICATION, UNSPECIFIED OPIOID DEPENDENCE, UNCOMPLICATED OPIOID DEPENDENCE, IN REMISSION OPIOID DEPENDENCE WITH INTOXICATION, UNCOMPLICATED OPIOID DEPENDENCE WITH INTOXICATION DELIRIUM OPIOID DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE OPIOID DEPENDENCE WITH INTOXICATION, UNSPECIFIED OPIOID DEPENDENCE WITH WITHDRAWAL OPIOID DEPENDENCE WITH OPIOID-INDUCED MOOD DISORDER OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED OPIOID DEPENDENCE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION OPIOID DEPENDENCE WITH OPIOID-INDUCED SLEEP DISORDER OPIOID DEPENDENCE WITH OTHER OPIOID-INDUCED DISORDER OPIOID DEPENDENCE WITH UNSPECIFIED OPIOID-INDUCED DISORDER OPIOID USE, UNSPECIFIED, UNCOMPLICATED CANNABIS ABUSE, UNCOMPLICATED December 27, 2018 Copyright 2018 Health Information Designs, LLC 5
6 ICD-10 Code F1220 F1221 F12220 F12221 F12222 F12229 F12250 F12251 F12259 F12280 F12288 F1229 F1290 F1310 F13120 F1320 F1321 F13220 F13221 F13229 F13230 F13231 F13232 F13239 F1324 F13250 F13251 Step 2 (diagnosis of alcohol or substance abuse) Description Required diagnosis: 1 Look back timeframe: 730 days CANNABIS DEPENDENCE, UNCOMPLICATED CANNABIS DEPENDENCE, IN REMISSION CANNABIS DEPENDENCE WITH INTOXICATION, UNCOMPLICATED CANNABIS DEPENDENCE WITH INTOXICATION DELIRIUM CANNABIS DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE CANNABIS DEPENDENCE WITH INTOXICATION, UNSPECIFIED CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH DELUSIONS CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER, UNSPECIFIED CANNABIS DEPENDENCE WITH CANNABIS-INDUCED ANXIETY DISORDER CANNABIS DEPENDENCE WITH OTHER CANNABIS-INDUCED DISORDER CANNABIS DEPENDENCE WITH UNSPECIFIED CANNABIS-INDUCED DISORDER CANNABIS USE, UNSPECIFIED, UNCOMPLICATED SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, UNCOMPLICATED SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION, UNCOMPLICATED SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION, UNCOMPLICATED SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION DELIRIUM SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION, UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNCOMPLICATED SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL DELIRIUM SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS December 27, 2018 Copyright 2018 Health Information Designs, LLC 6
7 ICD-10 Code F13259 F1326 F1327 F13280 F13281 F13282 F13288 F1329 F1390 F1410 F14120 F1420 F1421 F14220 F14221 F14222 F14229 F1423 F1424 F14250 F14251 F14259 F14280 F14281 F14282 F14288 F1429 Step 2 (diagnosis of alcohol or substance abuse) Description Required diagnosis: 1 Look back timeframe: 730 days SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING AMNESTIC DISORDER SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING DEMENTIA SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER SEDATIVE, HYPNOTIC, OR ANXIOLYTIC USE, UNSPECIFIED, UNCOMPLICATED COCAINE ABUSE, UNCOMPLICATED COCAINE ABUSE WITH INTOXICATION, UNCOMPLICATED COCAINE DEPENDENCE, UNCOMPLICATED COCAINE DEPENDENCE, IN REMISSION COCAINE DEPENDENCE WITH INTOXICATION, UNCOMPLICATED COCAINE DEPENDENCE WITH INTOXICATION DELIRIUM COCAINE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE COCAINE DEPENDENCE WITH INTOXICATION, UNSPECIFIED COCAINE DEPENDENCE WITH WITHDRAWAL COCAINE DEPENDENCE WITH COCAINE-INDUCED MOOD DISORDER COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED COCAINE DEPENDENCE WITH COCAINE-INDUCED ANXIETY DISORDER COCAINE DEPENDENCE WITH COCAINE-INDUCED SEXUAL DYSFUNCTION COCAINE DEPENDENCE WITH COCAINE-INDUCED SLEEP DISORDER COCAINE DEPENDENCE WITH OTHER COCAINE-INDUCED DISORDER COCAINE DEPENDENCE WITH UNSPECIFIED COCAINE-INDUCED DISORDER December 27, 2018 Copyright 2018 Health Information Designs, LLC 7
8 ICD-10 Code F1490 F1510 F15120 F1520 F1521 F15220 F15221 F15222 F15229 F1523 F1524 F15250 F15251 F15259 F15280 F15281 F15282 F15288 F1529 F1590 F1610 F16120 F1620 F1621 F16220 F16221 F16229 F1624 F16250 Step 2 (diagnosis of alcohol or substance abuse) Description Required diagnosis: 1 Look back timeframe: 730 days COCAINE USE, UNSPECIFIED, UNCOMPLICATED OTHER STIMULANT ABUSE, UNCOMPLICATED OTHER STIMULANT ABUSE WITH INTOXICATION, UNCOMPLICATED OTHER STIMULANT DEPENDENCE, UNCOMPLICATED OTHER STIMULANT DEPENDENCE, IN REMISSION OTHER STIMULANT DEPENDENCE WITH INTOXICATION, UNCOMPLICATED OTHER STIMULANT DEPENDENCE WITH INTOXICATION DELIRIUM OTHER STIMULANT DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE OTHER STIMULANT DEPENDENCE WITH INTOXICATION, UNSPECIFIED OTHER STIMULANT DEPENDENCE WITH WITHDRAWAL OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED MOOD DISORDER OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED ANXIETY DISORDER OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SLEEP DISORDER OTHER STIMULANT DEPENDENCE WITH OTHER STIMULANT-INDUCED DISORDER OTHER STIMULANT DEPENDENCE WITH UNSPECIFIED STIMULANT- INDUCED DISORDER OTHER STIMULANT USE, UNSPECIFIED, UNCOMPLICATED HALLUCINOGEN ABUSE, UNCOMPLICATED HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED HALLUCINOGEN DEPENDENCE, UNCOMPLICATED HALLUCINOGEN DEPENDENCE, IN REMISSION HALLUCINOGEN DEPENDENCE WITH INTOXICATION, UNCOMPLICATED HALLUCINOGEN DEPENDENCE WITH INTOXICATION WITH DELIRIUM HALLUCINOGEN DEPENDENCE WITH INTOXICATION, UNSPECIFIED HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED MOOD DISORDER HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS December 27, 2018 Copyright 2018 Health Information Designs, LLC 8
9 ICD-10 Code F16251 F16259 F16280 F16283 F16288 F1629 F1690 F1810 F18120 F1820 F1821 F18220 F18221 F18229 F1824 F18250 F18251 F18259 F1827 F18280 F18288 F1829 F1890 F1920 F1921 F19220 F19221 F19222 Step 2 (diagnosis of alcohol or substance abuse) Description Required diagnosis: 1 Look back timeframe: 730 days HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS) HALLUCINOGEN DEPENDENCE WITH OTHER HALLUCINOGEN-INDUCED DISORDER HALLUCINOGEN DEPENDENCE WITH UNSPECIFIED HALLUCINOGEN- INDUCED DISORDER HALLUCINOGEN USE, UNSPECIFIED, UNCOMPLICATED INHALANT ABUSE, UNCOMPLICATED INHALANT ABUSE WITH INTOXICATION, UNCOMPLICATED INHALANT DEPENDENCE, UNCOMPLICATED INHALANT DEPENDENCE, IN REMISSION INHALANT DEPENDENCE WITH INTOXICATION, UNCOMPLICATED INHALANT DEPENDENCE WITH INTOXICATION DELIRIUM INHALANT DEPENDENCE WITH INTOXICATION, UNSPECIFIED INHALANT DEPENDENCE WITH INHALANT-INDUCED MOOD DISORDER INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED INHALANT DEPENDENCE WITH INHALANT-INDUCED DEMENTIA INHALANT DEPENDENCE WITH INHALANT-INDUCED ANXIETY DISORDER INHALANT DEPENDENCE WITH OTHER INHALANT-INDUCED DISORDER INHALANT DEPENDENCE WITH UNSPECIFIED INHALANT-INDUCED DISORDER INHALANT USE, UNSPECIFIED, UNCOMPLICATED OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE, UNCOMPLICATED OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE, IN REMISSION OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION, UNCOMPLICATED OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION DELIRIUM OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE December 27, 2018 Copyright 2018 Health Information Designs, LLC 9
10 ICD-10 Code F19229 F19230 F19231 F19232 F19239 F1924 F19250 F19251 F19259 F1926 F1927 F19280 F19281 F19282 F19288 F1929 F550 F551 F552 F553 F554 F558 Step 2 (diagnosis of alcohol or substance abuse) Description Required diagnosis: 1 Look back timeframe: 730 days OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION, UNSPECIFIED OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL, UNCOMPLICATED OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL DELIRIUM OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED MOOD DISORDER OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING DEMENTIA OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL DYSFUNCTION OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SLEEP DISORDER OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH UNSPECIFIED PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER ABUSE OF ANTACIDS ABUSE OF HERBAL OR FOLK REMEDIES ABUSE OF LAXATIVES ABUSE OF STEROIDS OR HORMONES ABUSE OF VITAMINS ABUSE OF OTHER NON-PSYCHOACTIVE SUBSTANCES December 27, 2018 Copyright 2018 Health Information Designs, LLC 10
11 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null ACETAMINOPHEN-COD #2 TABLET ACETAMINOPHEN-COD #3 TABLET ACETAMINOPHEN-COD #4 TABLET ACETAMINOPHEN-CODEINE ELIXIR ACTIQ 1,200 MCG LOZENGE ACTIQ 1,600 MCG LOZENGE ACTIQ 200 MCG LOZENGE ACTIQ 400 MCG LOZENGE ACTIQ 600 MCG LOZENGE ACTIQ 800 MCG LOZENGE ALPRAZOLAM 0.25 MG ODT ALPRAZOLAM 0.25 MG TABLET ALPRAZOLAM 0.5 MG ODT ALPRAZOLAM 0.5 MG TABLET ALPRAZOLAM 1 MG ODT ALPRAZOLAM 1 MG TABLET ALPRAZOLAM 1 MG/ML ORAL CONC ALPRAZOLAM 2 MG ODT ALPRAZOLAM 2 MG TABLET ALPRAZOLAM ER 0.5 MG TABLET ALPRAZOLAM ER 1 MG TABLET ALPRAZOLAM ER 2 MG TABLET ALPRAZOLAM ER 3 MG TABLET ALPRAZOLAM XR 0.5 MG TABLET ALPRAZOLAM XR 1 MG TABLET ALPRAZOLAM XR 2 MG TABLET ALPRAZOLAM XR 3 MG TABLET AMBIEN 5 MG TABLET AMBIEN 10 MG TABLET AMBIEN CR 6.25 MG TABLET AMBIEN CR 12.5 MG TABLET ASCOMP WITH CODEINE CAPSULE AVINZA 120 MG CAPSULE AVINZA 60 MG CAPSULE AVINZA 90 MG CAPSULE BELLADONNA-OPIUM SUPP December 27, 2018 Copyright 2018 Health Information Designs, LLC 11
12 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null BELLADONNA-OPIUM SUPP BUNAVAIL MG FILM BUNAVAIL MG FILM BUNAVAIL 6.3-1MG FILM BUPRENEX 0.3 MG/ML AMPUL BUPRENORPHINE 2 MG TABLET SL BUPRENORPHINE 8 MG TABLET SL BUPRENORPHN-NALOXON MG SL BUPRENORPHN-NALOXON 8-2 MG SL BUTALB-CAFF-ACETAMINOPH-CODEIN BUTALB-CAFF-ACETAMINOPH-CODEIN BUTISOL SODIUM 30 MG TABLET BUTORPHANOL 10 MG/ML SPRAY BUTRANS 10 MCG/HR PATCH BUTRANS 15 MCG/HR PATCH BUTRANS 20 MCG/HR PATCH BUTRANS 5 MCG/HR PATCH BUTRANS 7.5 MCG/HR PATCH CAPITAL WITH CODEINE SUSP CARISOPRODOL CPD-CODEINE TAB CHLORDIAZEPOXIDE 5 MG CAPSULE CHLORDIAZEPOXIDE 10 MG CAPSULE CHLORDIAZEPOXIDE 25 MG CAPSULE CHLORDIAZEPOXIDE-CLIDINIUM CAPSULE CLONAZEPAM MG DIS TAB CLONAZEPAM 0.5 MG DIS TABLET CLONAZEPAM 1 MG DIS TABLET CLONAZEPAM 0.25 MG ODT CLONAZEPAM 2 MG ODT CLONAZEPAM 0.5 MG TABLET CLONAZEPAM 1 MG TABLET CLONAZEPAM 2 MG TABLET CLORAZEPATE 3.75 MG TABLET CLORAZEPATE 7.5 MG TABLET CLORAZEPATE 15 MG TABLET CODEINE SULFATE 30 MG TABLET December 27, 2018 Copyright 2018 Health Information Designs, LLC 12
13 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null CODEINE SULFATE 60 MG TABLET DEMEROL 100 MG/ML AMPUL DEMEROL 100 MG/ML VIAL DEMEROL 50 MG TABLET DEMEROL 50 MG/ML AMPUL DEMEROL 50 MG/ML AMPUL DEMEROL 50 MG/ML VIAL DEMEROL 75 MG/1.5 ML AMPUL DIAZEPAM 5 MG/ML ORAL CONC DIAZEPAM 2.5 MG RECTAL GEL DIAZEPAM 5 MG/5 ML SOLUTION DIAZEPAM 2 MG TABLET DIAZEPAM 5 MG TABLET DIAZEPAM 10 MG TABLET DIHYDROCODEIN-ACETAMINOPH-CAFF DILAUDID 2 MG TABLET DILAUDID 4 MG TABLET DILAUDID 8 MG TABLET DILAUDID-5 1 MG/ML LIQUID DILAUDID-HP 10 MG/ML AMPUL DILAUDID-HP 250 MG VIAL DOLOPHINE HCL 10 MG TABLET DURAGESIC 100 MCG/HR PATCH DURAGESIC 12 MCG/HR PATCH DURAGESIC 25 MCG/HR PATCH DURAGESIC 50 MCG/HR PATCH DURAGESIC 75 MCG/HR PATCH EDLUAR 5 MG SL TABLET EDLUAR 10 MG SL TABLET EMBEDA ER 100-4MG CAPSULE EMBEDA ER MG CAPSULE EMBEDA ER MG CAPSULE EMBEDA ER 50-2MG CAPSULE EMBEDA ER MG CAPSULE EMBEDA ER MG CAPSULE ENDOCET MG TABLET December 27, 2018 Copyright 2018 Health Information Designs, LLC 13
14 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null ENDOCET MG TABLET ENDOCET TABLET ENDOCET MG TABLET ESTAZOLAM 1 MG TABLET ESTAZOLAM 2 MG TABLET EXALGO ER 12 MG TABLET EXALGO ER 16 MG TABLET EXALGO ER 32 MG TABLET EXALGO ER 8 MG TABLET FENTANYL 100 MCG/HR PATCH FENTANYL 12 MCG/HR PATCH FENTANYL 25 MCG/HR PATCH FENTANYL 37.5 MCG/HR PATCH FENTANYL 50 MCG/HR PATCH FENTANYL 62.5 MCG/HR PATCH FENTANYL 75 MCG/HR PATCH FENTANYL 87.5 MCG/HR PATCH FENTANYL CIT OTFC 1,200 MCG FENTANYL CIT OTFC 1,600 MCG FENTANYL CITRATE OTFC 200 MCG FENTANYL CITRATE OTFC 400 MCG FENTANYL CITRATE OTFC 600 MCG FENTANYL CITRATE OTFC 800 MCG FENTORA 100 MCG BUCCAL TABLET FENTORA 200 MCG BUCCAL TABLET FENTORA 400 MCG BUCCAL TABLET FENTORA 600 MCG BUCCAL TABLET FENTORA 800 MCG BUCCAL TABLET FIORICET-COD CAP FIORINAL-COD CAP FLURAZEPAM 15 MG CAPSULE FLURAZEPAM 30 MG CAPSULE HYCET 7.5 MG-325 MG/15 ML SOL HYDROCODON-ACETAMINOPH HYDROCODON-ACETAMINOPH HYDROCODON-ACETAMINOPH December 27, 2018 Copyright 2018 Health Information Designs, LLC 14
15 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null HYDROCODON-ACETAMINOPHEN HYDROCODON-ACETAMINOPHEN HYDROCODON-ACETAMINOPHN HYDROCODON-ACETAMINOPHN HYDROCODONE-ACETAMINOPHEN SOLN HYDROCODONE BT-IBUPROFEN TAB HYDROCODONE-IBUPROFEN HYDROCODONE-IBUPROFEN HYDROCODONE-IBUPROFEN HYDROMORPHONE 1 MG/ML SOLUTION HYDROMORPHONE 10 MG/ML VIAL HYDROMORPHONE 2 MG TABLET HYDROMORPHONE 3 MG SUPPOS HYDROMORPHONE 4 MG TABLET HYDROMORPHONE 8 MG TABLET HYSINGLA ER 100MG TABLET HYSINGLA ER 120MG TABLET HYSINGLA ER 20MG TABLET HYSINGLA ER 30MG TABLET HYSINGLA ER 40MG TABLET HYSINGLA ER 60MG TABLET HYSINGLA ER 80MG TABLET IBUDONE MG TABLET IBUDONE MG TABLET KADIAN ER 10 MG CAPSULE KADIAN ER 100 MG CAPSULE KADIAN ER 20 MG CAPSULE KADIAN ER 200 MG CAPSULE KADIAN ER 30 MG CAPSULE KADIAN ER 50 MG CAPSULE KADIAN ER 60 MG CAPSULE KADIAN ER 80 MG CAPSULE KLONOPIN 0.5 MG TABLET KLONOPIN 1 MG TABLET KLONOPIN 2 MG TABLET LAZANDA 100MCG SPRAY/PUMP December 27, 2018 Copyright 2018 Health Information Designs, LLC 15
16 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null LAZANDA 300 MCG NASAL SPRAY LAZANDA 400MCG SPRAY/PUMP LEVORPHANOL 2 MG TABLET LORAZEPAM 0.5 MG TABLET LORAZEPAM 1 MG TABLET LORAZEPAM 2 MG TABLET LORAZEPAM 2 MG/ML VIAL LORAZEPAM 4 MG/ML VIAL LORAZEPAM INTENSOL 2 MG/ML LORCET MG TABLET LORCET HD MG TABLET LORCET PLUS MG TABLET LORTAB TABLET LORTAB TABLET LORTAB TABLET LUNESTA 1 MG TABLET LUNESTA 2 MG TABLET LUNESTA 3 MG TABLET MEPERIDINE 100 MG TABLET MEPERIDINE 100 MG/ML VIAL MEPERIDINE 25 MG/ML VIAL MEPERIDINE 50 MG TABLET MEPERIDINE 50 MG/5 ML SOLUTION MEPERIDINE 50 MG/ML VIAL MEPROBAMATE 200 MG TABLET MEPROBAMATE 400 MG TABLET METHADONE 10 MG/5 ML SOLUTION METHADONE 10 MG/ML ORAL CONC METHADONE 40 MG TABLET DISPR METHADONE 5 MG/5 ML SOLUTION METHADONE HCL 10 MG TABLET METHADONE HCL 5 MG TABLET METHADONE INTENSOL 10 MG/ML METHADOSE 10 MG TABLET METHADOSE 40 MG TABLET DISPR MORPHINE 10 MG/ML CARPUJECT December 27, 2018 Copyright 2018 Health Information Designs, LLC 16
17 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null MORPHINE 15 MG/ML CARPUJECT MORPHINE 15 MG/ML VIAL MORPHINE 2 MG/ML CARPUJECT MORPHINE 4 MG/ML CARPUJECT MORPHINE 8 MG/ML SYRINGE MORPHINE SULF 10 MG/5 ML SOLN MORPHINE SULF 100 MG/5 ML SOLN MORPHINE SULF 10MG/ML VIAL MORPHINE SULF 20 MG/5 ML SOLN MORPHINE SULF 5 MG/ML VIAL MORPHINE SULF 8 MG/ML VIAL MORPHINE SULF CR 15 MG TABLET MORPHINE SULF CR 30 MG TABLET MORPHINE SULF CR 60 MG TABLET MORPHINE SULF ER 100 MG TABLET MORPHINE SULF ER 200 MG TABLET MORPHINE SULFATE 50 MG/ML VIAL MORPHINE SULFATE ER 100MG CAP MORPHINE SULFATE ER 10MG CAP MORPHINE SULFATE ER 120MG CAP MORPHINE SULFATE ER 20MG CAP MORPHINE SULFATE ER 30MG CAP MORPHINE SULFATE ER 30MG CAP MORPHINE SULFATE ER 45MG CAP MORPHINE SULFATE ER 50MG CAP MORPHINE SULFATE ER 60MG CAP MORPHINE SULFATE ER 60MG CAP MORPHINE SULFATE ER 75MG CAP MORPHINE SULFATE ER 80 MG CAP MORPHINE SULFATE ER 90MG CAP MORPHINE SULFATE IR 15 MG TAB MORPHINE SULFATE IR 30 MG TAB MS CONTIN 100 MG TABLET MS CONTIN 15 MG TABLET MS CONTIN 200 MG TABLET December 27, 2018 Copyright 2018 Health Information Designs, LLC 17
18 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null MS CONTIN 60 MG TABLET MS CONTIN CR 30 MG TABLET NALBUPHINE 10 MG/ML AMPUL NALBUPHINE 200 MG/10 ML VIAL NIRAVAM 0.25 MG ODT NIRAVAM 0.5 MG ODT NIRAVAM 1 MG ODT NIRAVAM 2 MG ODT NORCO TABLET NUCYNTA 100 MG TABLET NUCYNTA 50 MG TABLET NUCYNTA 75 MG TABLET NUCYNTA ER 100MG TABLET NUCYNTA ER 150MG TABLET NUCYNTA ER 200MG TABLET NUCYNTA ER 250MG TABLET NUCYNTA ER 50MG TABLET OPANA 10 MG TABLET OPANA 5 MG TABLET OPANA ER 10 MG TABLET OPANA ER 15 MG TABLET OPANA ER 20 MG TABLET OPANA ER 30 MG TABLET OPANA ER 40 MG TABLET OPANA ER 5 MG TABLET OPANA ER 7.5 MG TABLET OPIUM TINCTURE 10 MG/ML OXAZEPAM 10 MG CAPSULE OXAZEPAM 15 MG CAPSULE OXAZEPAM 30 MG CAPSULE OXYCODON-ACETAMINOPHEN OXYCODONE-ACETAMINOPHEN OXYCODON-ACETAMINOPHEN OXYCODONE-ACETAMINOPHEN OXYCODONE-ASA TABLET OXYCODONE CONC 20 MG/ML SOLN December 27, 2018 Copyright 2018 Health Information Designs, LLC 18
19 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null OXYCODONE HCL 10 MG TABLET OXYCODONE HCL 10 MG TABLET ER OXYCODONE HCL 15 MG TABLET OXYCODONE HCL 20 MG TABLET OXYCODONE HCL 20 MG TABLET ER OXYCODONE HCL 30 MG TABLET OXYCODONE HCL 40 MG TABLET ER OXYCODONE HCL 5 MG CAPSULE OXYCODONE HCL 5 MG TABLET OXYCODONE HCL 5 MG/5 ML SOL OXYCODONE HCL ER 80 MG TABLET OXYCODONE-IBUPROFEN TAB OXYCONTIN 10 MG TABLET OXYCONTIN 15 MG TABLET OXYCONTIN 20 MG TABLET OXYCONTIN 30 MG TABLET OXYCONTIN 40 MG TABLET OXYCONTIN 60 MG TABLET OXYCONTIN 80 MG TABLET OXYMORPHONE HCL 5 MG TABLET OXYMORPHONE HCL 10 MG TABLET OXYMORPHONE HCL ER 10 MG TAB OXYMORPHONE HCL ER 15 MG TAB OXYMORPHONE HCL ER 20 MG TAB OXYMORPHONE HCL ER 30 MG TAB OXYMORPHONE HCL ER 40 MG TAB OXYMORPHONE HCL ER 5 MG TABLET OXYMORPHONE HCL ER 7.5 MG TAB PENTAZOCINE-NALOXONE TABLET PERCOCET MG TABLET PERCOCET MG TABLET PERCOCET MG TABLET PERCOCET MG TABLET PHENOBARBITAL 20 MG/5 ML ELIX PHENOBARBITAL 15 MG TABLET PHENOBARBITAL 16.2 MG TABLET December 27, 2018 Copyright 2018 Health Information Designs, LLC 19
20 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null PHENOBARBITAL 30 MG TABLET PHENOBARBITAL 32.4 MG TABLET PHENOBARBITAL 60 MG TABLET PHENOBARBITAL 64.8 MG TABLET PHENOBARBITAL 97.2 MG TABLET PHENOBARBITAL 100 MG TABLET PHENOBARBITAL 65 MG/ML VIAL PHENOBARBITAL 130 MG/ML VIAL REPREXAIN MG TABLET REPREXAIN MG TABLET REPREXAIN MG TABLET RESTORIL 7.5 MG CAPSULE RESTORIL 15 MG CAPSULE RESTORIL 22.5 MG CAPSULE RESTORIL 30 MG CAPSULE ROXICODONE 15 MG TABLET ROXICODONE 30 MG TABLET ROZEREM 8 MG TABLET SONATA 5 MG CAPSULE SONATA 10 MG CAPSULE SUBOXONE 12MG 3MG FILM SUBOXONE 2MG 0.5MG FILM SUBOXONE 4MG 1MG FILM SUBOXONE 8MG 2MG FILM TEMAZEPAM 7.5 MG CAPSULE TEMAZEPAM 15 MG CAPSULE TEMAZEPAM 22.5 MG CAPSULE TEMAZEPAM 30 MG CAPSULE TRAMADOL HCL 50 MG TABLET TRAMADOL HCL ER 100 MG TABLET TRAMADOL HCL ER 200 MG TABLET TRAMADOL-ACETAMINOPHN TRANXENE SD MG TABLET TRANXENE SD 22.5 MG TAB TRANXENE T-TAB 3.75 MG TRANXENE T-TAB 7.5 MG December 27, 2018 Copyright 2018 Health Information Designs, LLC 20
21 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null TRANXENE T-TAB 15 MG TRIAZOLAM 0.25 MG TABLET TRIAZOLAM MG TABLET TYLENOL WITH CODEINE #3 TABLET TYLENOL WITH CODEINE #4 TABLET ULTRACET TABLET ULTRAM 50 MG TABLET VICODIN TABLET VICODIN ES MG TABLET VICODIN HP MG TABLET VICOPROFEN MG TAB XANAX 0.25 MG TABLET XANAX 0.5 MG TABLET XANAX 1 MG TABLET XANAX 2 MG TABLET XANAX XR 0.5 MG TABLET XANAX XR 1 MG TABLET XANAX XR 2 MG TABLET XANAX XR 3 MG TABLET XARTEMIS XR MG TABLET XTAMPZA ER 9 MG CAPSULE XTAMPZA ER 13.5 MG CAPSULE XTAMPZA ER 18 MG CAPSULE XTAMPZA ER 27 MG CAPSULE XTAMPZA ER 36 MG CAPSULE XODOL TABLET XODOL MG TABLET XODOL TABLET ZALEPLON 5 MG CAPSULE ZALEPLON 10 MG CAPSULE ZEBUTAL CAPSULE ZOLPIDEM TART ER 6.25 MG TAB ZOLPIDEM TART ER 12.5 MG TAB ZOLPIDEM TARTRATE 5 MG TABLET ZOLPIDEM TARTRATE 10 MG TABLET ZUBSOLV MG TABLET SL December 27, 2018 Copyright 2018 Health Information Designs, LLC 21
22 Step 3 (active claim for CNS depressant) Required quantity: 1 Look back timeframe: Null ZUBSOLV MG TABLET SL ZUBSOLV MG TABLET SL ZUBSOLV MG TABLET SL ZUBSOLV MG TABLET SL ZUBSOLV MG TABLE SL ICD-10 Code G47411 G47419 G47421 G47429 Step 5 (diagnosis of narcolepsy or cataplexy) Description Required diagnosis: 1 Look back timeframe: 730 days NARCOLEPSY WITH CATAPLEXY NARCOLEPSY WITHOUT CATAPLEXY NARCOLEPSY IN CONDITIONS CLASSIFIED ELSEWHERE WITH CATAPLEXY NARCOLEPSY IN CONDITIONS CLASSIFIED ELSEWHERE WITHOUT CATAPLEXY December 27, 2018 Copyright 2018 Health Information Designs, LLC 22
23 Clinical Criteria References ICD-9-CM Diagnosis Codes Available at Accessed on April 3, ICD-10-CM Diagnosis Codes Available at Accessed on April 3, American Medical Association data files ICD-9-CM Diagnosis Codes. Available at 4. American Medical Association data files ICD-10-CM Diagnosis Codes. Available at 5. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; Available at Accessed on April 12, Micromedex [online database]. Available at Accessed on April 12, Xyrem Prescribing Information. Palo Alto, CA. Jazz Pharmaceuticals. July Krahn LE, Hershner S, Loeding LD, et al. Quality Measures for the Care of Patients with Narcolepsy. Journal of Clinical Sleep Medicine 2015;11(3): December 27, 2018 Copyright 2018 Health Information Designs, LLC 23
24 Publication History The Publication History records the publication iterations and revisions to this document. Notes for the most current revision are also provided in the Revision Notes on the first page of this document. Publication Date Notes 03/09/2011 Initial publication and posting to website 10/26/2011 Added a new section to specify the drugs requiring prior authorization Modified criteria logic and logic diagram to identify the steps that are executed manually In the Clinical Edit Criteria Supporting Tables section, revised tables to specify the drug names and s pertinent to steps 3 and 5 of the logic diagram In the Clinical Edit Criteria Supporting Tables section, revised tables to specify the diagnosis codes pertinent to steps 4 and 7 of the logic diagram 04/03/2015 Updated to include ICD-10s 04/12/2018 Annual review by staff Removed ICD-9 codes Updated logic and logic diagram, pages 3-4 Updated Table 3, page /27/2018 Updated step 1 of logic diagram, page 4. Yes = deny; No = go to #2 December 27, 2018 Copyright 2018 Health Information Designs, LLC 24
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationOpiate/Benzodiazepine/Muscle Relaxant Combinations
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Opiate/Benzodiazepine/Muscle Relaxant Combinations Clinical Edit Information Included in this Document Drugs requiring prior authorization:
More informationCapital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have
More informationPrior Authorization Opioid Overutilization 2017
Drugs Requiring Prior Authorization Label Name ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE CAPSULE ACETAMINOPHEN/CODEINE SOLUTION ACETAMINOPHEN/CODEINE TABLET ASCOMP/CODEINE CAPSULE BUTALBITAL/CAFFEINE/ACETAMINOPHEN/CODEINE
More informationGeneric Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
More informationOpioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
More informationPequot Health Care Opioid Analgesic Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits
More informationOpioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen
More informationOpioid Analgesic/Opioid Combination Products
Market DC Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit APAP/Caf/Dihydrocodeine 320.5mg/30mg/16mg APAP/Caf/Dihydrocodeine
More information20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days
Pre - PA Allowance Quantity Extended Release Tablets or Capsules 90 MME/day Medication Strength Avinza (morphine) 60mg, 75mg, 90mg Embeda (morphine /naltrexone) 50/2mg, 60/2.4mg, 80/3.2mg Exalgo (hydromorphone)
More informationAPPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
More informationOpioid Analgesic/Opioid Combination Products
Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit 320.5mg/30mg/16mg 356.4mg/30mg/16mg 325mg/30mg/16mg Trezix (new formulation)
More informationSection 2 Class III, IV & V Pharmaceuticals Page 13
Section 2 Class III, IV & V Pharmaceuticals Page 13 ACETAMINOPHEN W/ CODEINE #3 30MG TABS (GENERIC TYLENOL) #100 41.99 ACETAMINOPHEN W/ CODEINE #3 30MG TABS #1000 298.99 ACETAMINOPHEN W/ CODEINE #4 60MG
More informationFentanyl Agents Clinical Edit Criteria
Fentanyl Agents Clinical Edit Criteria Drug/Drug Class: Fentanyl Agents Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical edit criteria. Superior has adjusted
More informationNew Hampshire Healthy Families CLINICAL POLICY
New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:
More informationMorphine Equivalent Dosing
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by the Texas Medicaid Vendor Drug Program to ensure appropriate and safe utilization. Clinical
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationMEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111
POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335
More informationThe original MED criteria can be referenced at the Texas Vendor Drug Program website located at
Morphine Equivalent Dosing (MED) Clinical Edit Criteria Drug/Drug Class Morphine Equivalent Dosing (MED) Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioid Immediate Release Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioid Immediate Release Prime Therapeutics will review Prior Authorization
More informationCarefirst. +.V Family of health care plans
Family of health care plans Prior Authorization Form 1361M Opioids ER MME Limit and Post Limit This fax machine is located in a secure location as required by HPAA regulations. Complete/review information,
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationPrescription Drug Abuse: Colorado and Nationwide
Prescription Drug Abuse: Colorado and Nationwide Eric Lavonas, MD Associate Director, Rocky Mountain Poison and Drug Center Associate Professor, University of Colorado School of Medicine 1 What s the Problem?
More informationPrescription Drug Monitoring Reference Guide: 2017
Prescription Drug Monitoring Reference Guide: 2017 Prescription Drug Monitoring Test Codes Test Codes Drug/Drug Class P P,D,M P,D D,M D Alcohol Metabolites 90079 16910 92142 16217 Amphetamines 92222 70245
More informationChemaTox Blood Drug Testing Matrix (Updated May 24th, 2016)
ChemaTox Blood Drug Testing Matrix (Updated May 24th, 2016) Email: DREtox@chematox.com; Phone: (303)440-4500 Always identify any medications/drugs the suspect states they have taken, or that you suspect
More information: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
More informationCNS DEPRESSANT OVERDOSE
Signs and symptoms of CNS depressant overdose include: altered mental status, respiratory depression, hypotension, bradycardia, pulmonary edema, coma, and constricted pupils (opioids only). The following
More information1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationDrug Use Evaluation: Short Acting Opioids (SAO)
Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 3/12/16 11:14 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page Overview List of Medicines Recommended
More information15 mg morphine 10 mg hydrocodone
Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 04/27/2016 1:37 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page (http://www.fda.gov/aboutfda/aboutthiswebsite
More informationPrior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
More information10 mg hydrocodone equals how much oxycodone
Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationMorphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
More informationUrine Opioid Dependency Panel (UODP) 1
Drug Testing Panels Urine Opioid Dependency Panel (UODP) 1 Amphetamines Amphetamine Methamphetamine Methylenedioxyamphetamine Adderall, Dexedrine, Vyvanse, Lisdexamfetamine (Speed, Bennies, Crystal Meth,
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationHow To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist
How To Green My Pharmacy Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist Learning Objectives At the end of this presentation, pharmacists will be able to : 1. Understand the negative
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Provigil (Modafinil) Drugs requiring prior authorization: the list of drugs
More informationEquianalgesic Dosing of Opioids for Pain Management
PL Detail-Document #300405 This PL Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2014 Equianalgesic Dosing of Opioids for Pain Management
More informationMedication Policy Manual. Topic: Immediate-release (IR) Opioid Medication Products for Pain. Date of Origin: January 1, 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Immediate-release (IR) Opioid Medication Products for Pain Policy No: dru516 Date of Origin: January
More informationHarvard Pilgrim Health Care Prescription Drug List
Harvard Pilgrim Health Care Prescription Drug List PREMIUM FORMULARY THREE-TIER DRUG LIST (2016) BY CATEGORY This list is subject to change at any time. Harvard Pilgrim Health Care includes Harvard Pilgrim
More informationDisposal by Flushing of Certain Unused Medicines: What
Disposal by Flushing of Certain Unused Medicines: What You Should Know Drugs Page 1 of 5 Disposal by Flushing of Certain Unused Medicines: What You Should Know Overview Frequently Asked Questions List
More information1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationQUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA
DRUG CLASS QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME (generic) ARYMO ER (morphine sulfate extended-release tablets) AVINZA (morphine extended-release
More informationHarvard Pilgrim Health Care Prescription Drug List
Harvard Pilgrim Health Care Prescription Drug List PREMIUM FORMULARY THREE-TIER (2017) BY CATEGORY This list is subject to change at any time. Harvard Pilgrim Health Care includes Harvard Pilgrim Health
More informationTechnician Tutorial: Scheduled Drugs
(Page 1 of 8) Technician Tutorial: Scheduled Drugs In the U.S., the federal Controlled Substances Act (CSA) regulates controlled substances. The U.S. Drug Enforcement Administration (DEA), which is a part
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
More informationPrescription Drug Dispensing in Oregon
Drug Dispensing in Oregon January 1, 2012 - December 31, 2012 Schedules II-IV Medications Dispensed in Oregon Linn County PUBLIC HEALTH DIVISION Drug Monitoring Program Drug Dispensing in Oregon: January
More informationADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of drugs by drug class
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationSTEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules)
Carelirst. +.V Family of health care plans cvs caremarktm STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME* (generic)
More informationOpioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory
Opioids: Use, Abuse and Cause of Death Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory jharmon@occl.ocgov.com Opioid: Any psychoactive chemical that resembles morphine
More informationOpioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital
Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital Disclosure Davol/Bard Consultant Medtronic Physician Advisory Honorarium
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationPain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX
Pain Management and Compliance Toxicology Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX Prescription Drug Abuse: A National Problem Prescription drug abuse is a growing
More informationU T I L I Z A T I O N E D I T S
I N D I A N A H E A L T H C O V E R A G E P R O G R A M S U T I L I Z A T I O N E D I T S A P R I L 1 9, 2 0 1 2 s for s Refer to Provider Bulletin BT200709 for additional information regarding the Mental
More informationNarcotics in Workers Compensation
NCCI RESEARCH BRIEF December 2009 by Barry Lipton, Chris Laws, and Linda Li Narcotics in Workers Compensation Introduction Narcotics account for nearly one quarter of all workers compensation (WC) prescription
More informationOpiate Overutilization
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationOpioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
More informationHarvard Pilgrim Health Care Prescription Drug List
Harvard Pilgrim Health Care Prescription Drug List VALUE FORMULARY FIVE-TIER DRUG (2017) BY CATEGORY This list is subject to change at any time. Harvard Pilgrim Health Care includes Harvard Pilgrim Health
More informationAddressing Drug Diversion
Webinar Objectives Addressing Drug Diversion Bernice Burkarth, MD, HMDC, FAAHPM BBurkarth@treasurehealth.org October12, 2017 At the completion of this Webinar, participants will be able to: Identify tools
More informationCHANGES TO YOUR DRUG LIST
CHANGES TO YOUR DRUG LIST More generics and lower-cost brands to help you stay healthy and save money At Cigna, it s our goal to offer you access to coverage for safe, effective and affordable medications.
More informationLesson 5 - Regulations and Standards Assignment Answer Key
Assignment 1 Critical Thinking Question Lesson 5 - Regulations and Standards Assignment Answer Key 1. Should a health care organization punish individuals for reporting prescription errors that they made
More informationPARTICIPANT GENERAL INFORMATION
PARTICIPANT GENERAL INFORMATION Instructions: Please complete entire form (print) First name: Last Name: Other names used: Street address: City/State/Zip: County: Region: East TN Middle West Social Security
More informationHydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg
TE Te Hydrocodone 10mg vs oxycodone 10 mg What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg Manufacturer of oxycodone hcl 15 mg tablet side effects
More informationDipeptidyl Peptidase-4 (DPP-4) Inhibitors
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document DPP-4 Inhibitor Criteria A: Alogliptin 6.25mg, Januvia 25mg, Nesina 6.25mg, Onglyza
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationLidoderm (Lidocaine) Patch
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationINDIANA HEALTH COVERAGE PROGRAMS
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER CODE TABLES Division of Mental Health and Addiction (DMHA) Behavioral and Primary Healthcare Coordination (BPHC) Codes Note: Due to possible changes in Indiana
More informationAlprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
More informationADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 7/1/2017, Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of
More informationUrine Drug Testing Methods 3-5
Urine Drug Testing Methods 3-5 Type of Test Logistics Pearls Initial Screening Test: Immunoassay Confirmatory Test: Gas chromatography-mass spectrometry (GCMS) + or Liquid chromatography-mass spectrometry
More informationMethylnaltrexone Bromide (Relistor)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationOpioids, Extended Release (ER) Quantity Limit Criteria Program Summary
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is
More informationImmediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy
BENEFIT APPLICATION DRUG POLICY Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy Benefit determinations are based on the applicable
More informationHarvard Pilgrim Health Care Prescription Drug List
Harvard Pilgrim Health Care Prescription Drug List VALUE FORMULARY FIVE-TIER DRUG (2018) BY CATEGORY This list is subject to change at any time. Harvard Pilgrim Health Care includes Harvard Pilgrim Health
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3053-9 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
More information10 BEFORE THE MEDICAL BOARD OF CALIFORNIA Kimberly Kirchmeyer ("Complainant") brings this Accusation solely in her official
2 3 4 5 6 7 XAVIER BECERRA Attorney General of California MATTHEW M. DAVIS Supervising Deputy Attorney General JOHNS. GATSCHET Deputy Attorney General State Bar No. 244388 California Department of Justice
More informationHarvard Pilgrim Health Care Prescription Drug List
Harvard Pilgrim Health Care Prescription Drug List PREMIUM FORMULARY THREE-TIER (2018) BY CATEGORY This list is subject to change at any time. Harvard Pilgrim Health Care includes Harvard Pilgrim Health
More informationPerformCare Provider Network Scott Daubert PhD, VP Provider Network & Account Management. AD ICD-10-CM Frequently Asked Questions
Provider Notice To: From: PerformCare Provider Network Scott Daubert PhD, VP Provider Network & Account Management Date: April 23, 2015 Subject: AD 15 105 ICD-10-CM Frequently Asked Questions The Centers
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization
More informationAmitiza (Lubiprostone)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationDiclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class, Diclofenac 1.5% and 2% Topical Solution This criteria was recommended for review by an MCO to ensure appropriate and safe utilization
More informationPrescription Drug Monitoring and Toxicology ICD-10-CM. resource guide. Provided as a service of Quest Diagnostics. 1 ICD-10-CM Resource Guide
Prescription Drug Monitoring and Toxicology ICD-10-CM resource guide Provided as a service of Quest Diagnostics 1 ICD-10-CM Resource Guide Table of contents About ICD-10 3 Pain Management: Top Mappings
More informationNational 800 Phone Number. What is Misuse? Iowa s PCC. Commonly Misused Rx Drugs. Pharmageddon: The Rx Drug Abuse Crisis 04/07/14 1
Pharmageddon: The Rx Drug Abuse Crisis National 800 Phone Number Works just like 911 Program your cell phone! Linda B. Kalin, RN, BS, CSPI Director Linda.Kalin@unitypoint.org Hotline: 800-222-1222 Office:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationProposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)
Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure
More information